Keeping Track: FDA Clears Celltrion's Biosimilar Inflectra; Review Activity In OIC Picks Up
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Gilead's Descovy May Have Problem Getting HIV Prevention Indication In Cisgender Women
Descovy demonstrated noninferiority to Truvada in men and transgender women who have sex with men, but pharmacokinetic data do not support a demonstration of pre-exposure prophylaxis efficacy in cisgender women, US FDA says in advisory committee briefing document.
Investor Conference Business Updates, In Brief
Amgen, Celgene, Mylan and Gilead were among the companies that provided business updates at the Cowen and Co. Healthcare conference and Raymond James Institutional Investors conference.
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.